Journal of Antimicrobial Chemotherapy (2000) 45, 95-99
© 2000 The British Society for Antimicrobial Chemotherapy
Serum itraconazole concentrations and clinical responses in Candida-associated denture stomatitis patients treated with itraconazole solution and itraconazole capsules
a University of Glasgow Dental School, Level 2, 378 Sauchiehall Street, Glasgow G2 3JZ; b Public Health Laboratory Service Mycology Reference Laboratory, Bristol, UK
The aim of this study was to compare the concentrations of itraconazole in serum and saliva after treatment with itraconazole cyclodextrin solution or itraconazole capsules in Candida-associated denture stomatitis patients without evidence of immunodeficiency. Forty patients were randomly assigned to receive either itraconazole cyclodextrin solution or itraconazole capsules, both at a dosage of 100 mg bd for 15 days. On completion of treatment palatal erythema was assessed and an oral rinse and imprint cultures were collected. Serum and saliva samples were collected at the same time and itraconazole concentrations measured using reverse-phase high-performance liquid chromatography. Itraconazole susceptibilities of Candida albicans and Candida glabrata strains isolated at baseline were measured by a broth microdilution method. Serum itraconazole concentrations achieved did not differ significantly between the two preparations (P = 0.39) although a significantly higher number of patients in the itraconazole cyclodextrin group (P < 0.001) had detectable levels of itraconazole in their saliva compared with the capsule group. Mycologically cured patients had slightly, though not significantly (P = 0.28), higher serum itraconazole concentrations than those from whom yeasts were not eradicated. It was concluded that both formulations of itraconazole were equally effective in treatment of denture stomatitis. Among immunocompetent patients, the absorption of the liquid preparation is no greater than that of the capsules. Therapeutic success in this group was achieved with lower serum itraconazole concentrations than have been reported for immunocompromised groups.
* Corresponding author. Tel: +44-141-211-9831; Fax: +44-141-353-1593; E-mail: L.Cross{at}dental.gla.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. H. Shin, H. J. Jung, H. R. Kim, J. Jeong, S. H. Jeong, S. Kim, E. Y. Lee, J. N. Lee, and C. L. Chang Prevalence, Characteristics, and Molecular Epidemiology of Macrolide and Fluoroquinolone Resistance in Clinical Isolates of Streptococcus pneumoniae at Five Tertiary-Care Hospitals in Korea Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2625 - 2627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Touyama, F. Higa, C. Nakasone, T. Shinzato, M. Akamine, S. Haranaga, M. Tateyama, I. Nakasone, N. Yamane, and J. Fujita In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV J. Antimicrob. Chemother., December 1, 2006; 58(6): 1279 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. V. Piddock Clinically Relevant Chromosomally Encoded Multidrug Resistance Efflux Pumps in Bacteria Clin. Microbiol. Rev., April 1, 2006; 19(2): 382 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. MacGowan and K. E. Bowker Mechanism of Fluoroquinolone Resistance Is an Important Factor in Determining the Antimicrobial Effect of Gemifloxacin against Streptococcus pneumoniae in an In Vitro Pharmacokinetic Model Antimicrob. Agents Chemother., March 1, 2003; 47(3): 1096 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-i. Yokota, K. Sato, O. Kuwahara, S. Habadera, N. Tsukamoto, H. Ohuchi, H. Akizawa, T. Himi, and N. Fujii Fluoroquinolone-Resistant Streptococcus pneumoniae Strains Occur Frequently in Elderly Patients in Japan Antimicrob. Agents Chemother., October 1, 2002; 46(10): 3311 - 3315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Madaras-Kelly, C. Daniels, M. Hegbloom, and M. Thompson Pharmacodynamic characterization of efflux and topoisomerase IV-mediated fluoroquinolone resistance in Streptococcus pneumoniae J. Antimicrob. Chemother., August 1, 2002; 50(2): 211 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. V. Piddock and M. M. Johnson Accumulation of 10 Fluoroquinolones by Wild-Type or Efflux Mutant Streptococcus pneumoniae Antimicrob. Agents Chemother., March 1, 2002; 46(3): 813 - 820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Fluit, M. R. Visser, and F.-J. Schmitz Molecular Detection of Antimicrobial Resistance Clin. Microbiol. Rev., October 1, 2001; 14(4): 836 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-R. Hsueh, L.-J. Teng, T.-L. Wu, S.-W. Ho, and K.-T. Luh First clinical isolate of Streptococcus pneumoniae exhibiting high-level resistance to fluoroquinolones in Taiwan J. Antimicrob. Chemother., August 1, 2001; 48(2): 316 - 317. [Full Text] [PDF]
|
|
|
|
|
|
P. L. Ho, W. C. Yam, T. L. Que, D. N. C. Tsang, W. H. Seto, T. K. Ng, and W. S. Ng Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones J. Antimicrob. Chemother., May 1, 2001; 47(5): 655 - 658. [Abstract] [Full Text] [PDF]
|
|